

Immuno-oncology and Tumorigenesis

Reference	Address
Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> . 2020;5(6):e001079.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703447/pdf/esmooopen-2020-001079.pdf
American Cancer Society (ACS). About Melanoma Akin Cancer. Key statistics for melanoma skin cancer. Revised January 12, 2021. Accessed April 15, 2021.	https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html
Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. <i>J Clin Oncol</i> . 2015;33(25):2780-2788.	https://ascopubs.org/doi/10.1200/JCO.2014.58.3377
Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncol</i> . 2020;21(11):1465-1477.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30494-0/fulltext
Choueiri TK, et al. A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk. <i>J Clin Oncol</i> . 2020;38(15 suppl):TPS5102.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS5102
Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. <i>Ann Oncol</i> . 2020;31(8):1030-1039.	https://www.annalsofncology.org/article/S0923-7534(20)39308-X/fulltext
Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. <i>N Engl J Med</i> . 2021;384(9):829-841.	https://www.nejm.org/doi/10.1056/NEJMoa2026982
Eggermont AM, Blank CU, Mandalà M, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. <i>J Clin Oncol</i> . 2020;38(15 suppl):10000.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.10000
Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648545/

ipilimumab adjuvant therapy. <i>N Engl J Med</i> . 2016;375(19):1845-1855.	
Eggermont AM, et al. LBA46. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial. <i>Ann Oncol</i> . 2020;31(suppl 4):S1175.	https://scihub.se/10.1016/j.annonc.2020.08.2276
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>N Engl J Med</i> . 2018 May 10;378(19):1789-1801.	https://www.nejm.org/doi/10.1056/NEJMoa1802357
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>CA Cancer J Clin</i> . 2017;67(6):472-492.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29028110/
Grünwald V, Powles T, Choueiri TK, et al. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale. <i>Future Oncol</i> . 2019;15(9):929-941.	https://www.futuremedicine.com/doi/abs/10.2217/fon-2018-0745
Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced <i>BRAF</i> ^{V600} mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> . 2020;395(10240):1835-1844.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30934-X/fulltext
Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. <i>J Clin Oncol</i> . 2009;27(34):5794-5799.	https://ascopubs.org/doi/pdf/10.1200/JCO.2008.21.4809
Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncol</i> . 2018;19(11):1480-1492.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30700-9/fulltext
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. <i>N Engl J Med</i> . 2010;363:711-723.	https://www.nejm.org/doi/pdf/10.1056/NEJMOA1003466
Yervoy® (ipilimumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; November 2020.	https://packageinserts.bms.com/pi/pi_yervoy.pdf

Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. <i>Nat Rev Clin Oncol</i> . 2019;16:621-633.	https://www.nature.com/articles/s41571-019-0209-1
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N Engl J Med</i> . 2019;381(16):1535-1546.	https://www.nejm.org/doi/10.1056/NEJMoa1910836
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). <i>Cancer Res</i> . 2017;77(13 suppl):CT075.	https://cancerres.aacrjournals.org/content/77/13_Supplement/CT075
Lebbé C, Meyer N, Mortier L, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: Results from the phase IIIb/IV CheckMate 511 Trial. <i>J Clin Oncol</i> . 2019;37(11):867-875.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311280/
Lebbé, Meyer N, Mortier L, et al. 4311 - Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). Presented at ESMO 2018.	https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/Initial-results-from-a-phase-3b-4-study-evaluating-two-dosing-regimens-of-nivolumab-NIVO-in-combination-with-ipilimumab-IPI-in-patients-with-advanced-melanoma-CheckMate-511
Lee CH, Shah AY, Hsieh JJ, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). <i>J Clin Oncol</i> . 2020;38(15 suppl):5008.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5008
Lee CH, Motzer RJ. Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer. <i>Nat Rev Nephrol</i> . 2017;13(2):69-70.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC54100904/
Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: Disease-specific approaches to therapy. <i>Clin Cancer Res</i> . 2004;10(18 Pt 2):6282S-6289S.	https://clincancerres.aacrjournals.org/content/10/18/6282S
Long GV, Schacter J, Ribas L, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. <i>J Clin Oncol</i> . 2018;36(suppl):9503.	https://meetinglibrary.asco.org/record/159075/abstract
MacArthur GE, Stroyakovskiy D, Gogas H, et al. CT012 - Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with <i>BRAF</i> ^{V600} mutation-positive advanced	https://www.abstractsonline.com/pp8/#!/9045/presentation/10594

melanoma: Primary results from the phase 3 IMspire150 trial. Presented at AACR 2020.	
Manning EA, Ullman JGM, Leatherman JM, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. <i>Clin Cancer Res.</i> 2007;13(13):3951-3959.	https://clincancerres.aacrjournals.org/content/13/13/3951
Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. <i>Nat Med.</i> 2014;20(6):607-615	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24793239/
Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. <i>N Engl J Med.</i> 2021;384(14):1289-1300.	https://www.nejm.org/doi/full/10.1056/NEJMoa2035716
Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. <i>J Immunother Cancer.</i> 2020;8(2):e000891.	https://jitc.bmj.com/content/jitc/8/2/e000891.full.pdf
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. <i>N Engl J Med.</i> 2007;356(2):115-124.	https://www.nejm.org/doi/10.1056/NEJMoa065044
Motzer RJ, Penkov K, Hannen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <i>N Engl J Med.</i> 2019;380(12):1103-1115.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30779531/
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. <i>N Engl J Med.</i> 2018;378(14):1277-1290.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29562145/
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. Version 2.2021. Published February 19, 2021.	https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Kidney cancer Version 3.2021. Published March 23, 2021.	https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03). NCT04338269. Updated April 1, 2021. Accessed April 16, 2021.	https://clinicaltrials.gov/ct2/show/NCT04338269

Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: The many faces of renal cell carcinoma. <i>Rev Urol.</i> 2002;4(4):163-170.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC16985675/
Keytruda® (pembrolizumab) [package insert] Whitehouse Station NJ: Merck & Co, Inc; March 2021.	https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf
Plimack ER, Rini BI, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. <i>J Clin Oncol.</i> 2020;38(15 suppl):5001.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.5001
Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2020;21(12):1563-1573.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30436-8/fulltext
Ribas A. Tumor immunotherapy directed at PD-1. <i>N Engl J Med.</i> 2012;366(26):2517-2519.	https://www.nejm.org/doi/10.1056/NEJMe1205943
Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. <i>N Engl J Med.</i> 2019;380:1116-1127.	https://www.nejm.org/doi/10.1056/NEJMoa1816714
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. <i>N Engl J Med.</i> 2015;372(4):320-330.	https://www.nejm.org/doi/10.1056/NEJMoa1412082
Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicenter, randomised, controlled, phase 3 study. <i>Lancet Oncol.</i> 2019;20:1239-1251.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30388-2/fulltext
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. <i>N Engl J Med.</i> 2015;372(26):2521-2532.	https://www.nejm.org/doi/10.1056/NEJMoa1503093
Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. <i>Cancer Immun.</i> 2008;8:1.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC18198818/
Schreiber RD, Old LJ, Smyth MJ. et al. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. <i>Science</i> 2011;331:1565-1570.	https://science.sciencemag.org/content/331/6024/1565
Seuradge J, Wong E. Melanoma. In: <i>McMaster Pathophysiol Review.</i> Accessed April 17, 2021.	http://www.pathophys.org/melanoma/
Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and	https://cancerres.aacrjournals.org/content/70/15/6171.long

enhance the effectiveness of adoptive immunotherapy of cancer. <i>Cancer Res.</i> 2010;70(15):6171-6180.	
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. <i>J Clin Oncol.</i> 2010;28(6):1061-1068.	https://ascopubs.org/doi/10.1200/JCO.2009.23.9764
Tawbi HA, Forsyth PA, Hodi FS, et al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). <i>J Clin Oncol.</i> 2019;37(15 suppl):9501.	https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9501
Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. <i>N Engl J Med.</i> 2018;379(8):722-730.	https://www.nejm.org/doi/10.1056/NEJMoa1805453
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. <i>N Engl J Med.</i> 2017;377(19):1824-1835.	https://www.nejm.org/doi/10.1056/NEJMoa1709030
Weber JS, Kurt M, Edmondson-Jones M, et al. 3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial. <i>Ann Oncol.</i> 2019;30(suppl 5):v533-v563.	https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/Mixture-cure-modeling-for-resected-stage-III-IV-melanoma-in-the-phase-3-CheckMate-238-trial
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N Engl J Med</i> 2017;377:1345-1356.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28889792/
Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. <i>Clin Cancer Res.</i> 2009;15(23):7412-7420.	https://clincancerres.aacrjournals.org/content/15/23/7412
Llovet JM, Villanueva A, Marrero JA, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference. <i>Hepatology.</i> 2021;73(suppl 1):158-191.	https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.31327
Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. <i>Nat Rev Clin Oncol.</i> 2018;15(10):599-616.	https://www.nature.com/articles/s41571-018-0073-4?WT.feed_name=subjects_cancer-therapy
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. <i>Cell.</i> 2011;144(5):646-674.	https://www.cell.com/cell/fulltext/S0092-8674(11)00127-9
Morse MA, Sun W, Kim R, et al. The role of angiogenesis in hepatocellular carcinoma. <i>Clin Cancer Res.</i> 2019;25(3):912-920.	http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=30274981
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. <i>Immunity.</i> 2013;39(1):1-10.	https://www.cell.com/immunity/fulltext/S1074-7613(13)00296-3

Chen DS, Hurwitz H. Combinations of bevacizumab with cancer immunotherapy. <i>Cancer J</i> . 2018;24(4):193-204	https://pubmed.ncbi.nlm.nih.gov/30119083/
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges . <i>Nat Rev Clin Oncol</i> . 2018;15(5):325-340.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC629508855/
Greten TF, Sangro B. Targets for immunotherapy of liver cancer. <i>J Hepatol</i> . 2018;68:157-166.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC628923358/
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet</i> . 2017;389(10088):2492-2502.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC628434648/
Kudo M, Matilla A, Santoro A, et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. <i>J Clin Oncol</i> . 2019;37(4 suppl):327.	https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.327
Kudo M, Matilla A, Santoro A, et al. LB-2. Nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma (aHCC) in the CheckMate-040 study. Presented at AASLD 2018.	https://plan.core-apps.com/tristar_aasld18/abstract/1cd464b79336d9176dd9c2472ad1b769
Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. <i>Lancet Oncol</i> . 2018;19(7):940-952.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30351-6/fulltext
Zhu AX, Finn RS, Cattan S, et al. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>J Clin Oncol</i> . 2018;36(4 suppl):209.	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.209
Yau T, Park JW, Finn RS, et al. LBA38_PR. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). <i>Ann Oncol</i> . 2019;30(suppl 5):v874-v875.	https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2819%2960389-3
Finn RS, Ryoo BY, Merle P, et al. Results of KEYNOTE-240: Phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). <i>J Clin Oncol</i> . 2019;37(suppl):4004.	https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.4004
Datta M, Coussens LM, Nishikawa H, et al. Reprogramming the tumor microenvironment to improve immunotherapy: Emerging strategies and	https://ascopubs.org/doi/full/10.1200/EDBK_237987

combination therapies. <i>ASCO Educational Book</i> . 2019;39:165-174.	
Shigeta K, Datta M, Hato T, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. <i>Hepatology</i> . 2020;71(4):1247-1261.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31378984/
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. <i>N Engl J Med</i> . 2020;382(20):1894-1905.	https://www.nejm.org/doi/10.1056/NEJMoa1915745
Finn RS, Qin S, Ikeda M, et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). <i>J Clin Oncol</i> . 2021;39(3 suppl):267.	https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.267
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer. NCT04163237. Last updated November 14, 2019. Accessed April 17, 2021.	https://clinicaltrials.gov/ct2/show/NCT04163237
Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. <i>J Clin Oncol</i> . 2020;38(26):2960-2970.	https://ascopubs.org/doi/10.1200/JCO.20.00808
Columbus G. The FDA has granted a breakthrough therapy designation to the combination of pembrolizumab and lenvatinib for the first-line treatment of patients with advanced unresectable hepatocellular carcinoma that is not amenable to locoregional therapy. <i>OncLive</i> . Published July 23, 2019. Accessed April 17, 2021.	www.onclive.com/view/fda-grants-breakthrough-designation-to-frontline-pembrolizumablenvatinib-for-hcc
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. <i>N Engl J Med</i> . 2015;373(2):123-135.	https://pubmed.ncbi.nlm.nih.gov/26028407/
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. <i>N Engl J Med</i> . 2015;373(17):1627-1639.	https://pubmed.ncbi.nlm.nih.gov/26412456/
Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. <i>N Engl J Med</i> . 2020;383(14):1328-1339.	https://pubmed.ncbi.nlm.nih.gov/32997907/
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell	https://pubmed.ncbi.nlm.nih.gov/30280635/

lung cancer. <i>N Engl J Med</i> . 2018;379(21):2040-2051.	
Paz Ares LG, Luft A, Tafreshi A, et al. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). <i>J Clin Oncol</i> . 2018;36(15 suppl):105.	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.105
West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncol</i> . 2019;20(7):924-937.	https://pubmed.ncbi.nlm.nih.gov/31122901/
Spigel D, de Marinis F, Giaccone G, et al. LBA78. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. <i>Ann Oncol</i> . 2019;30(suppl 5):v915.	https://www.annalsofoncology.org/article/S0959-6638(19)60359-5/pdf
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. <i>N Engl J Med</i> . 2018;378(22):2078-2092.	https://pubmed.ncbi.nlm.nih.gov/29658856/
Ghandi L, Rodríguez-Abreu D, Gadgeel S, et al. Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC. <i>Cancer Res</i> . 2018;78(13 suppl):CT075.	https://cancerres.aacrjournals.org/content/78/13_Supplement/CT075
Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. <i>N Engl J Med</i> . 2017;376(25):2415-2426.	https://pubmed.ncbi.nlm.nih.gov/28636851/
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. <i>N Engl J Med</i> . 2016;375(19):1823-1833.	https://pubmed.ncbi.nlm.nih.gov/27718847/
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. <i>N Engl J Med</i> . 2017;377(20):1919-1929.	https://pubmed.ncbi.nlm.nih.gov/28885881/
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy	https://pubmed.ncbi.nlm.nih.gov/30280658/

in stage III NSCLC. <i>N Engl J Med</i> . 2018;379(24):2342-2350.	
Abbas A, Lichtman A, Pillai S. <i>Cellular and Molecular Immunology</i> . 10th ed. Elsevier; 2012.	https://www.elsevier.com/books/cellular-and-molecular-immunology/abbas/978-0-323-75748-5
Mellman I, Coukos G, Dranoff G, et al. Cancer immunotherapy comes of age. <i>Nature</i> . 2011;480(7378):480-489.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22193102/
Boudreau JE, Bonehill A, Thielmans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. <i>Mol Ther</i> . 2011;19(5):841-853.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21468005/
Murphy KM, Weaver C. <i>Janeway's Immunobiology</i> . 9th ed. WW Norton & Co; 2016.	https://www.amazon.com/Immunobiology-Janeway-Charles-Travers-Shlomchik/dp/B00BTM716E https://www.routledge.com/Janeways-Immunobiology/Murphy-Weaver/p/book/9780429084881
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. <i>Nat Rev Cancer</i> . 2012;12(4):252-264.	https://www.nature.com/articles/nrc3239.pdf
Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. <i>CA Cancer J Clin</i> . 2012;62(5):309-335.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22576456/
Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. <i>N Engl J Med</i> . 2018;378(22):2093-2104.	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29658845/
Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer <i>J Clin Oncol</i> . 2020;38(14):1505-1517.	https://pubmed.ncbi.nlm.nih.gov/32150489/
Xin Yu J, Hubbard-Lucey VM, Tang J. Immunoncology drug development goes global. <i>Nat Rev Drug Discov</i> . 2019;18(12):899-900.	https://pubmed.ncbi.nlm.nih.gov/31780841/
Velcheti V, Kim ES, Mekhail T, et al. Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. <i>J Clin Oncol</i> . 2018;36(15 suppl):12001.	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.12001

Adverse Events

Resource	Address
----------	---------

<p>Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2018;36(17):1714-1768.</p>	<p>https://ascopubs.org/doi/pdf/10.1200/JCO.2017.77.6385</p>
<p>Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. <i>Ann Oncol</i>. 2016;27(4):559-574.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/26715621/</p>
<p>Chen DS. Immuno-oncology combination therapies. Presented at American Association for Cancer Research (AACR), 2017.</p>	<p>https://webcast.aacr.org/console/player/35110?mediaType=audio&</p>
<p>Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. <i>Clin Cancer Res</i>. 2015;21(5):1071-1077.</p>	<p>https://clincancerres.aacrjournals.org/content/21/5/1071.long</p>
<p>Choueiri TK, Albiges L, Haanen JBAGm, et al. Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). <i>J Clin Oncol</i>. 2019;37(15 suppl):101.</p>	<p>https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.101</p>
<p>Corrie P. Immune checkpoint inhibitors: A new class of anticancer drug. <i>Prescriber</i>. 2016;27(7):23-28.</p>	<p>https://wchh.onlinelibrary.wiley.com/doi/epdf/10.1002/psb.1479</p>
<p>Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. <i>Ann Oncol</i>. 2017;28(suppl 5):621-622.</p>	<p>https://www.annalsofoncology.org/article/S0923-7534(20)39129-8/fulltext</p>
<p>Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. <i>Nat Rev Clin Oncol</i>. 2014;11(2):91-99.</p>	<p>https://doi.org/10.1038/nrclinonc.2013.245</p>
<p>Madden KM, Hoffner B. Ipilimumab-based therapy: Consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events with ipilimumab monotherapy and combination therapy with nivolumab. <i>Clin J Oncol Nurs</i>. 2017;21(4 suppl):30-41.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28738054/</p>
<p>McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC29867230/</p>

renal cell carcinoma. <i>Nat Med</i> . 2018;24(6):749-757.	
Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. <i>Eur J Cancer</i> . 2016;54:139-148.	https://www.ejancer.com/article/S0959-8049(15)01112-0/fulltext
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. <i>N Engl J Med</i> . 2015;373(19):1803-1813.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC26406148/
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. <i>N Engl J Med</i> . 2018;378(14):1277-1290.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC29562145/
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. <i>N Engl J Med</i> . 2018;378(2):158-168.	https://www.nejm.org/doi/10.1056/NEJMra1703481
Postow MA. Managing immune checkpoint-blocking antibody side effects. <i>Am Soc Clin Oncol Educ Book</i> . 2015;35:76-83.	https://ascopubs.org/doi/10.14694/EdBook_AM.2015.35.76
Postow MA. Toxicities associated with checkpoint inhibitor immunotherapy. <i>UpToDate</i> . Updated April 2, 2021. Accessed April 18, 2021.	https://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy
Powles T, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. <i>J Clin Oncol</i> . 2019;37(7 suppl):543.	https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.543
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. <i>J Immunother Cancer</i> . 2017;5(1):95.	https://jitc.biomedcentral.com/track/pdf/10.1186/s40425-017-0300-z
Shields AF, Jacobs PM, Sznol M, et al. Immune modulation therapy and imaging: Workshop report <i>J Nucl Med</i> . 2018;59(3):410-417.	https://ijnm.snmjournals.org/content/59/3/410.1ong
Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. <i>J Clin Oncol</i> . 2012;30(21):2691-2697.	http://ascopubs.org/doi/full/10.1200/jco.2012.41.6750
Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. <i>J Clin Oncol</i> . 2015;33(18):2092-2099.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC25918278/

<p>Sangro B, Melero I, Yau T, et al. Nivolumab in sorafenib-naive and -experienced patients with advanced hepatocellular carcinoma (HCC): Survival, hepatic safety, and biomarker assessments in CheckMate 040. Presented at AASLD The Liver Meeting 2017. Abstract 141.</p>	<p>https://www.natap.org/2017/AASLD/AASLD_34.htm</p>
<p>Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: A comprehensive review including current and alternative management strategies <i>Expert Opin Drug Metab Toxicol</i>. 2019;15(3):231-244.</p>	<p>https://www.tandfonline.com/doi/full/10.1080/17425255.2019.1574744</p>
<p>Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. <i>N Engl J Med</i>. 2011;364(26):2517-2526.</p>	<p>https://www.nejm.org/doi/10.1056/NEJMoa1104621</p>
<p>Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. <i>J Clin Oncol</i>. 2012;30(17):2046-2054.</p>	<p>https://ascopubs.org/doi/10.1200/JCO.2011.38.4032</p>
<p>Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. <i>Ann Oncol</i>. 2013;24(1):75-83.</p>	<p>https://www.annalsofoncology.org/article/S0923-7534(19)37026-7/fulltext</p>
<p>Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncol</i>. 2014;15(7):700-712.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC24831977/</p>
<p>Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial. <i>Lancet Oncol</i>. 2015;16(5):522-530.</p>	<p>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70122-1/fulltext</p>
<p>Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. <i>J Clin Oncol</i>. 2013;31(5):616-622.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC23295794/</p>

<p>Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. <i>N Engl J Med</i>. 2015;373(2):123-135.</p>	<p>https://www.nejm.org/doi/full/10.1056/nejmoa1504627</p>
<p>Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. <i>N Engl J Med</i>. 2015;373:1627-1639.</p>	<p>https://www.nejm.org/doi/full/10.1056/nejmoa1507643</p>
<p>Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. <i>Lancet</i>. 2016;387(10031):1909-1920.</p>	<p>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00561-4/fulltext</p>
<p>Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial. <i>J Thorac Oncol</i>. 2020;15(8):1351-1360.</p>	<p>https://www.jto.org/article/S1556-0864(20)30292-6/fulltext</p>
<p>Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>N Engl J Med</i>. 2015;372(21):2006-2017.</p>	<p>https://www.nejm.org/doi/full/10.1056/nejmoa1414428</p>
<p>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. <i>N Engl J Med</i>. 2015;373(1):23-34.</p>	<p>https://www.nejm.org/doi/full/10.1056/nejmoa1504030</p>
<p>Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. <i>N Engl J Med</i>. 2013;369(2):122-133.</p>	<p>https://www.nejm.org/doi/full/10.1056/nejmoa1302369</p>
<p>Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. <i>J Clin Oncol</i>. 2004;22(14 suppl):6098.</p>	<p>https://ascopubs.org/doi/abs/10.1200/jco.2004.22.90140.6098</p>
<p>Miller ED, Abu-Sbeih H, Styskel B, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. <i>Am J Gastroenterol</i>. 2020;115(2):251-261.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31789632/</p>
<p>Abu-Sbeih H, Styskel B, Blechacz B, et al. Clinically significant hepatotoxicity due to immune checkpoint inhibitors is rare but leads to treatment discontinuation in a high proportion. <i>Hepatology</i>. 2018;68(suppl 1):25A-26A.</p>	<p>https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.30256</p>

Cunningham M, et al. Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor (CPI) immunotherapy. Presented at International Liver Congress (ILC) 2019: abstract PS-139.	https://easl.eu/wp-content/uploads/2019/04/Best-of-ILC2019_Liver-tumours-v1.0-190413.pptx
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 4.2021. Published March 3, 2021. Accessed March 5, 2021.	https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Biomarkers

Resource	Address
Barlesi F, Park K, Ciardiello F, et al. LBA44_PR. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. <i>Ann Oncol</i> . 2016;27(suppl 6):vi552-vi587.	https://www.annalsofoncology.org/article/S0923-7534(19)45268-X/fulltext
Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. <i>Nature</i> . 2013;499(7457):214-218.	https://www.nature.com/articles/nature12213
Lu S, Stein JE, Rimm DL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: A systematic review and meta-analysis. <i>JAMA Oncol</i> . 2019;5(8):1195-1204.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC631318407/
McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. <i>JAMA Oncol</i> . 2016;2(1):46-54.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC426562159/
Melero I, Neely J, Sangro B, et al. Abstract 2675: Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040. <i>Cancer Res</i> . 2019;79(13 suppl):2675.	https://cancerres.aacrjournals.org/content/79/13_Supplement/2675
Peters S, Creelan B, Hellmann MD, et al. Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026. <i>Cancer Res</i> . 2017;77(13 suppl):CT082.	https://cancerres.aacrjournals.org/content/77/13_Supplement/CT082

Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. <i>Lancet</i> . 2017;389(10066):255-265.	https://pubmed.ncbi.nlm.nih.gov/27979383/
Sangro B, Melero I, Wadhawan S, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. <i>J Hepatol</i> . 2020;73(6):1460-1469.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC732710922/
Schalper KA. Current status of biomarkers for cancer immunotherapy. Presented at ASCO 2017.	https://meetinglibrary.asco.org/record/138156/slides
Singal AG, Hoshida Y, Pinato DJ, et al. International Liver Cancer Association (ILCA) white paper on biomarker development for hepatocellular carcinoma [published online ahead of print, 2021 Mar 8]. <i>Gastroenterology</i> . 2021;S0016-5085(21)00518-7.	https://www.gastrojournal.org/article/S0016-5085(21)00518-7/pdf
Skoulidis F, Goldberg ME, Greenawalt DM, et al. <i>STK11/LKB1</i> mutations and PD-1 inhibitor resistance in <i>KRAS</i> -mutant lung adenocarcinoma. <i>Cancer Discov</i> . 2018;8(7):822-835.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC629773717/
Soria JC, Flatten O, Horn L, et al. 33LBA Efficacy and safety of pembrolizumab (pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001. <i>Eur J Cancer</i> . 2015;51(suppl 3):S726-S727.	https://www.ejancer.com/article/S0959-8049(15)30077-0/fulltext
Tsao MS. Can we select the right patient for immunotherapy in NSCLC? The pathologist's point of view. Presented at ESMO 2016.	https://oncologypro.esmo.org/meeting-resources/esmo-2016/Can-we-select-the-right-patient-for-immunotherapy-in-NSCLC-The-pathologist-s-point-of-view
Velcheti V, et al. OA 13.02. Distribution of PD-L1 Tumor Expression by Assay Type in Patients with Metastatic NSCLC (MNSCLC). <i>J Thor Oncol</i> . 2017;12(11 suppl 2):S1779-S1780.	https://www.jto.org/action/showPdf?pii=S1556-0864%2817%2931137-1
Velcheti V, Kim ES, Mekhail T, et al. Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-FIRST results. <i>J Clin Oncol</i> . 2018;36(15 suppl):12001.	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.12001

Resource	Address
American Society of Clinical Oncology (ASCO). COVID-19 vaccines and patients with cancer. Updated April 16, 2021. Accessed April 18, 2021.	https://www.asco.org/asco-coronavirus-resources/covid-19-vaccines-patients-cancer
American Society of Clinical Oncology (ASCO). Cancer treatment & supportive care. Updated April 1, 2021. Accessed April 18, 2021.	www.asco.org/asco-coronavirus-resources/care-individuals-cancer-during-covid-19/cancer-treatment-supportive-care
Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. <i>Immunotherapy</i> . 2020;12(5):269-273.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117596/
Centers for Disease Control and Prevention (CDC). Discontinuation of transmission-based precautions and disposition of patients with SARS-CoV-2 infection in healthcare settings. Updated February 16, 2021. Accessed April 18, 2021.	www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html
Fung M, Babik JM. COVID-19 in immunocompromised hosts: What we know so far. <i>Clin Infect Dis</i> . 2021;72(2):340-350.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337668/pdf/ciaa863.pdf
Kattan J, Kattan C, Assi T. Do checkpoint inhibitors compromise the cancer patients' immunity and increase the vulnerability to COVID-19 infection? <i>Immunotherapy</i> . 2020;12(6):351-354.	https://www.futuremedicine.com/doi/pdf/10.2217/imt-2020-0077
Lee LYW, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. <i>Lancet</i> . 2020;395(10241):1919-1926.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255715/pdf/main.pdf
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. <i>Lancet Oncol</i> . 2020;21(3):335-337.	https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(20)30096-6.pdf
Miyashita H, Mikami N, Chopra T, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City, <i>Ann Oncol</i> . 2020;31(8):1088-1089.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172785/pdf/main.pdf
National Comprehensive Cancer Network (NCCN). Short-term recommendations for cutaneous melanoma management during COVID-19 pandemic. Version 3. Published May 6, 2020. Accessed April 18, 2021.	https://www.nccn.org/docs/default-source/covid-19/2021-covid-nccn-melanoma.pdf .
Pinato DJ, Zambelli A, Aguilar-Company J, et al. Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer. <i>Cancer Discov</i> . 2020;10(10):1465-1474.	https://cancerdiscovery.aacrjournals.org/content/10/10/1465.long

Rossi E, Schinzari G, Tortora G. Pneumonitis from immune checkpoint inhibitors and COVID-19: Current concern in cancer treatment. <i>J Immunother Cancer</i> . 2020;8(2):e000952.	https://jitc.bmj.com/content/jitc/8/2/e000952.full.pdf
---	---

Multidisciplinary Approaches and Shared Decision-Making

Resource	Address
Agency for Healthcare Research and Quality (AHRQ). The share approach: A model for shared decision making. Accessed April 18, 2021.	www.ahrq.gov/sites/default/files/publications/files/share-approach_factsheet.pdf
Agency for Healthcare Research and Quality (AHRQ). The SHARE approach essential steps of shared decision making: Quick reference guide. Workshop curriculum: Tool 1. Published April 2014. Accessed April 18, 2021.	https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/shareddecisionmaking/tools/tool-1/share-tool1.pdf
Albiges L, Rini BI, Haanen J, et al. Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase 3 JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC). <i>Ann Oncol</i> . 2019;30(suppl 5):v359-v360.	https://www.annalsofoncology.org/article/S0959-7534(19)59124-4/pdf
Back A. Patient-physician communication in oncology: what does the evidence show? <i>Oncology (Williston Park)</i> . 2006;20(1):67-74; discussion 77-78, 83.	http://www.cancernetwork.com/oncology-journal/patient-physician-communication-oncology-what-does-evidence-show
Chang TT, Sawhney R, Monto A, et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. <i>HPB (Oxford)</i> . 2008;10(6):405-411.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC19088925/
Daniels GA, Guerrero AD, Katz D, Viets-Upchurch J. Challenge of immune-mediated adverse reactions in the emergency department. <i>Emerg Med J</i> . 2019;36(6):369-377.	https://emj.bmj.com/content/emj/36/6/369.full.pdf
Frerichs W, Hahlweg P, Müller E, et al. Shared decision-making in oncology – A qualitative analysis of healthcare providers’ views on current practice. <i>PLoS One</i> . 2016;11(3):e0149789.	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0149789
Hawley ST, Jagsi R. Shared decision making in cancer care: Does one size fit all? <i>JAMA Oncol</i> . 2015;1(1):58-59.	https://jamanetwork.com/journals/jamaoncology/fullarticle/2108848
Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ. Management of immune checkpoint inhibitor	https://www.ncbi.nlm.nih.gov/pubmed/30120013

<p>toxicities: A review and clinical guideline for emergency physicians. <i>J Emerg Med.</i> 2018;55(4):489-502.</p>	
<p>Medendorp NM, Visser LNC, Hillen MA, de Haes JCJM, Smets EMA. How oncologists' communication improves (analogue) patients' recall of information. A randomized video-vignettes study. <i>Patient Educ Couns.</i> 2017;100(7):1338-1344.</p>	<p>https://www.sciencedirect.com/science/article/abs/pii/S0738399117300769</p>
<p>Pallin DJ, Baugh CW, Postow MA, et al. Immune-related adverse events in cancer patients. <i>Acad Emerg Med.</i> 2018;25(7):819-827.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMID29729100/</p>
<p>Serper M, Taddei TH, Mehta R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. <i>Gastroenterology.</i> 2017;152(8):1954-1964.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28283421/</p>
<p>Visser LNC, Tollenaar MS, van Doornen LJP, de Haes HCJM, Smets EMA. Does silence speak louder than words? The impact of oncologists' emotion-oriented communication on analogue patients' information recall and emotional stress. <i>Patient Educ Couns.</i> 2019;102(1):43-52.</p>	<p>https://www.sciencedirect.com/science/article/abs/pii/S0738399118306323</p>
<p>Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. <i>Ann Surg Oncol.</i> 2014;21(4):1287-1295.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC24318095/</p>
<p>Zhang J, Mavros MN, Cosgrove D, et al. Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. <i>Curr Oncol.</i> 2013;20(2):e123-e131.</p>	<p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615863/pdf/conc-20-e123.pdf</p>